Search Results 481-490 of 18028 for Alopecia

  1. CAST-AI: Cystectomy after systemic therapy with ADC and Immunotherapy - Mayo Clinic

    ... alopecia) or conditions requiring hormonal replacement therapies such as type 1 diabetes mellitus or hypothyroidism are permitted to enroll * Known ...

  2. Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia - Mayo Clinic

    * All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to NCI CTCAE version 5.0 Grade≤ 1 * Adequate organ function * Must ...

  3. A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression - Mayo Clinic

    Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE v.3.0 Grade ≤ 1 and to baseline laboratory values as defined in the ...

  4. Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer - Mayo Clinic

    ... alopecia and peripheral neuropathy. Have adequate organ function, including: Hematologic: absolute neutrophil count ≥1.5 × 10⁹/Liter (L), platelets ≥100 ...

  5. Sym021 in Combination with Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients with Advanced Biliary Tract Carcinomas - Mayo Clinic

    ... alopecia not requiring systemic treatment, conditions not expected to recur in the absence of an external trigger. Patients with a history of organ ...

  6. A Study of APG-2575 Alone or in Combination with Other Therapeutic Agents to Treat Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) - Mayo Clinic

    Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have not recovered to ≤ grade 1 or baseline, except alopecia or neuropathy.

  7. A Study to Test the Addition of Nivolumab to Chemotherapy to Treat Soft Tissue Sarcoma - Mayo Clinic

    ... alopecia. Taxane Naive Patients Only: No prior exposure to taxane therapy of any duration for angiosarcoma. Taxane Pre-treated Patients Only: Prior taxane ...

  8. T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer - Mayo Clinic

    ... alopecia and peripheral neuropathy =< grade 1 - Adequate excision: surgical removal of all clinically evident disease in the breast and lymph nodes as ...

  9. A Phase Ⅲ Study Of Rilvegostomig In Combination With Fluoropyrimidine And Trastuzumab Deruxtecan As The First-line Treatment For HER2-positive Gastric Cancer - Mayo Clinic

    Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Note: Participants may be ...

  10. Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies - Mayo Clinic

    Participants with Grade 2 neuropathy or Grade 2 alopecia are eligible. - Active idiopathic thrombocytopenic purpura. - Stem cell transplant < 100 days prior ...